Activity Overview

The management of hormone receptor-positive, HER2-negative (HR+/HER2–) metastatic breast cancer has undergone rapid evolution in recent years with the development of novel endocrine and targeted therapies designed to address critical unmet needs in selected patients. Navigating the treatment landscape now depends on appropriate molecular testing, as well as patient- and disease-related features, to make effective management decisions.

This live, hybrid symposium brings together expert faculty in the management of HR+/HER2– metastatic breast cancer to discuss best practices for selecting treatment for patients, covering topics ranging from timing and type of molecular testing to treatment based on biomarker status. The content is presented in the Show Me the Data format, which is designed to focus on specific decision points as well as the findings that justify management decisions.

This educational activity is an archive of the live virtual symposium held at the 43rd Annual Miami Breast Cancer Conference^® on March 6, 2026.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, oncology nurses, advanced practice professionals, pathologists, and other health care practitioners who manage patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Implement best practices for molecular testing in HR+/HER2– metastatic breast cancer, including selection of tissue vs liquid biopsy and indications for repeat testing at progression
Apply clinical trial and real-world evidence to select and sequence oral selective estrogen receptor degraders (SERDs) after progression on a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor plus endocrine therapy
Develop treatment strategies for dual resistance, integrating evidence for targeting the PI3K/AKT pathway in patients with co-occurring ESR1 and PIK3CA pathway alterations

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Stemline Therapeutics, Inc.

Show Me the Data™: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer

GET STARTED WITH THIS PROGRAM:

Related Content